Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -10794.00% is 43% below its 5-year average of -7550.07%, near the high end of its 5-year range (-43803.33%–-3678.07%).
33.73% above its 12-month average of -16289.09%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -5548.89%.
EBITDA MARGIN
-10794.00%
EBITDA MARGIN AVG TTM
-16289.09%
EBITDA MARGIN AVG 3Y
-7765.07%
EBITDA MARGIN AVG 5Y
-7550.07%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+33.73%
CURRENT VS 3Y AVG
-39.01%
CURRENT VS 5Y AVG
-42.97%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Clene Inc.
Market Cap
$49.96M
EBITDA Margin
-10794.00%
TTM Avg
-16289.09%
3Y Avg
-7765.07%
5Y Avg
-7550.07%
Market Cap
$50.25M
EBITDA Margin
-9115.35%
TTM Avg
-8798.34%
3Y Avg
-6751.54%
5Y Avg
-5839.94%
Market Cap
$49.50M
EBITDA Margin
-203.44%
TTM Avg
-129.78%
3Y Avg
-288.25%
5Y Avg
-438.27%
Market Cap
$50.51M
EBITDA Margin
-108.45%
TTM Avg
-10676.44%
3Y Avg
-10454.97%
5Y Avg
-429870.64%
Market Cap
$52.95M
EBITDA Margin
-36.23%
TTM Avg
-36.23%
3Y Avg
-36.23%
5Y Avg
-36.23%
Market Cap
$53.01M
EBITDA Margin
-5927.25%
TTM Avg
-3470.39%
3Y Avg
-2050.54%
5Y Avg
-1465.25%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clene Inc. (CLNN) | $49.96M | -10794.00% | -16289.09% | -7765.07% | -7550.07% |
| Envoy Medical, Inc. (COCH)vs › | $50.25M | -9115.35% | -8798.34% | -6751.54% | -5839.94% |
| Celularity Inc. (CELU)vs › | $49.50M | -203.44% | -129.78% | -288.25% | -438.27% |
| Apollomics, Inc. (APLM)vs › | $50.51M | -108.45% | -10676.44% | -10454.97% | -429870.64% |
| biote Corp. (BTMD)vs › | $49.40M | 20.40% | 19.12% | 4.66% | 12.12% |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.95M | -36.23% | -36.23% | -36.23% | -36.23% |
| ImageneBio Inc (IMA)vs › | $53.01M | -5927.25% | -3470.39% | -2050.54% | -1465.25% |
| BioStem Technologies, Inc. (BSEM)vs › | $46.79M | -0.99% | 4.72% | -25.09% | -32.37% |
Gross Margin
78.5%
EBITDA Margin
-10794.0%
Operating Margin
-11541.5%
Net Margin
-20059.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -5548.89% |
| 2026-03-31 | -11373.33% |
| 2025-12-31 | -8940.26% |
| 2025-09-30 | -35220.00% |
| 2025-06-30 | -20362.96% |
| 2025-03-31 | -4533.33% |
| 2024-12-31 | -9065.93% |
| 2024-09-30 | -8516.09% |
| 2024-06-30 | -7667.03% |
| 2024-03-31 | -12071.23% |
| 2023-12-31 | -5592.94% |
| 2023-09-30 | -8428.70% |
| 2023-06-30 | -3678.07% |
| 2023-03-31 | -9654.21% |
| 2022-12-31 | -4814.10% |
| 2022-09-30 | -5501.15% |
| 2022-06-30 | -38022.86% |
| 2022-03-31 | -43803.33% |
| 2021-12-31 | -6953.27% |
| 2021-09-30 | -9286.36% |
| 2021-06-30 | -6726.37% |
| 2021-03-31 | -5376.06% |
| 2020-12-31 | -19631.03% |
| 2020-09-30 | -5569.39% |
| 2020-06-30 | -47955.56% |
| 2020-03-31 | -5405.71% |
